Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 10/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5848909 | 0.88 | MAPK11 (0.36) | MAPK11MAPK14MAPK13MAPK12CHRNB4 | |
| SCHEMBL5847748 | 0.71 | AURKA (0.40) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL5849792 | 0.69 | KDM1A (0.43) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL5849788 | 0.69 | KDM1A (0.43) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL8232486 | 0.69 | GSK3B (0.58) | — | |
| SCHEMBL6516598 | 0.67 | MAPK11 (0.34) | MAPK11MAPK14MAPK13MAPK12ADRA1A | |
| SCHEMBL5848215 | 0.65 | ALDH1A1 (0.36) | MAPK11MAPK14KCNH2 | |
| SCHEMBL21135457 | 0.65 | FFAR1 (0.58) | CHRNA7CHRNB2CDK1 | |
| SCHEMBL21135481 | 0.65 | FFAR1 (0.58) | CHRNA7CHRNB2CDK1 | |
| SCHEMBL5847982 | 0.65 | MDM2 (0.35) | MAPK11MAPK14CHRNA7CHRNB2ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-02-17 | — | — | US | claimed |
| US-7026326-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2006-04-11 | — | — | US | disclosed |
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | AMGEN, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038010-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | MAPK11 1540/4885MAPK14 2458/4885MAPK13 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.